UniQure will continue manufacturing hemophilia gene therapy candidate AMT-061 after selling the licensing rights to CSL Behring. CSL Behring has paid uniQure $450 million for the global rights to commercialize the adeno-associated virus (AAV) gene therapy candidate AMT-061 (etranacogene dezaparvovec), in late stage studies for the treatment of hemophilia B. UniQure could be entitled to up to $1.6 billion depending on the progress of the candidate. The addition to CSL Behring supports the firm’s advanced therapy ambitions, according to company…